Sana Biotechnology, Inc.
Sana Biotechnology, Inc. is a U.S.-based biotechnology company focused on developing engineered cell and gene therapies. Its work centers on ex vivo and in vivo cell engineering platforms designed to create medicines for diseases such as type 1 diabetes, oncology, and B cell mediated autoimmune disorders.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaEngineered cells modified outside the body and then administered as therapies.
Therapies and delivery systems intended to modify cells directly inside the body.
Platform technologies aimed at reducing immune rejection of engineered cells.
Cell-targeting delivery programs based on licensed fusogen technology.
Product candidates and supporting development work across therapeutic areas.
Asiakkaat
Sana does not sell commercial products today; its direct counterparties are primarily research institutions, licensors, CDMOs, and clinical trial service providers that support development. If its programs succeed, the eventual customers would be hospitals, physicians, payors, and patients in specialty therapeutic areas such as diabetes, oncology, and autoimmune disease. The business model is therefore centered on advancing product candidates through development rather than serving a traditional recurring customer base.
Universities and biotech partners that provide licensed platform technologies and IP used to build Sana's cell engineering programs.
External manufacturing and research organizations that produce clinical material and run parts of development programs.
Hospitals and research centers that enroll patients and generate clinical data for product candidates.
Physicians and treatment centers that would administer approved cell and gene therapies.
Commercial and government payors that would determine coverage and access for approved therapies.
Strategia
Sana's strategy is to build engineered cell medicines by combining acquired and in-licensed technologies into ex vivo and in vivo platforms. It is also investing in manufacturing science, process analytics, and external manufacturing capabilities so that product candidates can move from research into clinical and, eventually, commercial supply. Intellectual property protection, platform differentiation, and selective partnerships are central to its competitive position.
The company needs clinical proof that its engineered cell approaches can become approvable medicines.
Cell therapies require reliable clinical and future commercial supply, often through specialized external manufacturing.
The platform depends on licensed and proprietary technologies that must remain protected to support differentiation.
Development-stage biotech requires ongoing capital to fund trials, manufacturing, and regulatory work.
Maantiede
Sana is headquartered in the United States and operates as a U.S.-based development-stage biotechnology company. Its licensed technologies and patent rights extend across multiple jurisdictions, and its clinical, manufacturing, and regulatory activities may involve partners and trial sites in the U.S. and other countries. Geography matters mainly through access to research talent, regulatory pathways, manufacturing partners, and global intellectual property protection.
Riskit
Sana faces the typical risks of a development-stage cell and gene therapy company: clinical failure, regulatory setbacks, manufacturing complexity, and dependence on third parties. Its platform also relies on licensed and acquired technologies, so IP disputes, license restrictions, or inability to secure additional rights could materially affect development. Funding risk is significant because the company has not commercialized products and must finance ongoing research, trials, and manufacturing buildout.
- Financing and going-concern riskVaikutus: KriittinenTodennäköisyys: Korkea
The company must raise additional capital to fund R&D, trials, and commercialization efforts.
Kohdistuu: Corporate funding and operating runway
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea
Product candidates may not meet FDA or foreign regulator requirements for safety and efficacy.
Kohdistuu: Ex vivo and in vivo programs across multiple indications
- Manufacturing and supply chain disruptionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Cell therapy manufacturing is complex and depends on specialized materials, processes, and third parties.
Kohdistuu: Clinical supply and future commercial supply
- Third-party dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company relies on CDMOs, CROs, licensors, and research partners to execute core development activities.
Kohdistuu - Intellectual property and licensing riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Programs depend on licensed technologies and patent protection that could be challenged or restricted.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätExternal trial and manufacturing services are recognized based on estimates, so timing differences can shift expenses between periods.
Vaikutus: Operating expense volatility
Upfront payments for acquired technologies may be expensed immediately if there is no alternative future use.
Vaikutus: Large one-time R&D charges
Acquired technologies must be assessed for recoverability and may be written down if assumptions weaken.
Vaikutus: Non-cash impairment charges
Future payments under technology agreements can affect expense timing and cash needs.
Vaikutus: R&D expense and liquidity
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
KALA BIO, Inc
KALA · Pharmaceutical Preparations
Genprex, Inc.
GNPX · Pharmaceutical Preparations
Calidi Biotherapeutics, Inc.
CLDWW · Biological Products, (No Diagnostic Substances)
Rani Therapeutics Holdings, Inc.
RANI · Pharmaceutical Preparations
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
Sunhydrogen, Inc.
HYSR · Semiconductors & Related Devices
Päivitetty: 24.9.2026